doi:10.3969/j.issn.1673-8640.2019.09.017

Abstract

CLC Number:

R446.1

Figures/Tables 5

References 8

[1]	李家泰. 临床药理学[M]. 3版. 北京:人民卫生出版社,2007:472.
[2]	武剑,冯新红. 神经系统疾病中的整合式精准医疗[J]. 中华医学杂志,2015,95(31):2515-2517.
[3]	NAGASAKI T,OHKUBO T,SUGAWARA K,et al.Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia[J]. J Pharm Biomed Anal,1999,19(3-4):595-601.
[4]	HIEMKE C,BAUMANN P,BERGEMANN N,等. AGNP精神科治疗药物监测共识指南:2011[J]. 李文标,果伟,阮灿军,等,译. 实用药物与临床,2016,19(10):1193-1218.
[5]	林治光,李华芳,翁毅仁,等. HPLC-电化学检测法测定人血清中利培酮及9-羟利培酮浓度[J]. 四川精神卫生,2007,20(2):65-68.
[6]	AVENOSOA,FACCIOLÀ G,SALEMI M,et al.Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection[J]. J Chromatogr B Biomed Sci Appl,2000,746(2):173-181.
[7]	段小涛,陈笑艳,张逸凡,等. 液相色谱-串联质谱法测定人血浆中的利培酮[J]. 药学学报,2016,64(7):684-688.
[8]	周逸雯,周琰,吴炯,等. CYP3A4、CYP3A5和CYP2D6基因单核苷酸多态性对肾移植术后稳定期患者他克莫司代谢的影响[J]. 检验医学,2015,30(11):1091-1095.

项目	理论值（ng/mL）	日内			日间
项目	理论值（ng/mL）	实测值（ng/mL）	回收率（%）	RSD（%）	实测值（ng/mL）	回收率（%）	RSD（%）
利培酮	10	10.03	100.30	4.18	9.89	98.90	6.88
	20	18.45	92.25	6.40	20.17	100.85	8.87
	50	48.72	97.44	5.32	48.72	99.64	6.54
9-羟利培酮	10	9.69	96.90	4.85	9.88	9.88	5.06
	20	20.07	100.35	6.08	19.78	98.90	7.79
	50	49.02	98.04	5.67	50.17	100.34	6.08

项目	理论值（ng/mL）	日内			日间
项目	理论值（ng/mL）	实测值（ng/mL）	回收率（%）	RSD（%）	实测值（ng/mL）	回收率（%）	RSD（%）
利培酮	10	10.03	100.30	4.18	9.89	98.90	6.88
	20	18.45	92.25	6.40	20.17	100.85	8.87
	50	48.72	97.44	5.32	48.72	99.64	6.54
9-羟利培酮	10	9.69	96.90	4.85	9.88	9.88	5.06
	20	20.07	100.35	6.08	19.78	98.90	7.79
	50	49.02	98.04	5.67	50.17	100.34	6.08

项目	-80 ℃反复冻融			室温放置			烈日暴晒
项目	1次	2次	3次	2 h	24 h	48 h	1 d	2 d
利培酮
高浓度	108.2	103.4	99.5	98.2	101.3	97.7	99.2	103.4
低浓度	97.5	108.7	98.5	101.7	98.2	103.6	97.9	89
9-羟利培酮
高浓度	98.7	102.2	100.6	102.6	99.2	106.5	101.2	99
低浓度	99.6	101.4	102.7	96.5	104.7	105.2	98.7	101.2

项目	-80 ℃反复冻融			室温放置			烈日暴晒
项目	1次	2次	3次	2 h	24 h	48 h	1 d	2 d
利培酮
高浓度	108.2	103.4	99.5	98.2	101.3	97.7	99.2	103.4
低浓度	97.5	108.7	98.5	101.7	98.2	103.6	97.9	89
9-羟利培酮
高浓度	98.7	102.2	100.6	102.6	99.2	106.5	101.2	99
低浓度	99.6	101.4	102.7	96.5	104.7	105.2	98.7	101.2

患者序号	剂量（mg/d）	利培酮		9-羟利培酮
患者序号	剂量（mg/d）	HP LC-电化学法	CE-MS法	HPLC-电化学法	CE-MS法
1	1	1.8	1.84	5.2	5.32
2	1	2.4	2.54	4.7	4.99
3	2	5.7	6.02	16.8	17.14
4	2	4.2	4.39	20.1	22.04
5	3	15.2	18.14	21.9	23.73
6	3	2.7	3.25	8.6	9.15

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 8

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.